Skip to main content
Premium Trial:

Request an Annual Quote

Genoox Raises $6M in New Funding

NEW YORK (GenomeWeb) – Genomic analysis startup Genoox announced today that it has raised $6 million in a new funding round.

Genoox's next-generation sequencing technology employs machine learning algorithms to analyze large amounts of genetic data. The Tel Aviv, Israel-based company entered the US market in 2017 and raised $6 million in a Series A round last June.

The current financing round was led by Triventures, and also included Inimiti Capital and Glilot Capital Partners.

"As a doctor, having access to personalized medicine will transform how we provide care and empower us to deliver the right treatment at the right time," Triventures Cofounder and Managing Partner Peter Fitzgerald said in a statement. "The platform makes it simple and cost-effective to identify the genetic root causes of disease and medical issues, and has even identified new genetic variants that have enabled parents to save their children's lives." Fitzgerald has also joined Genoox's board.

In April, Genoox partnered with Bionano Genomics to develop a genome informatics workflow, which integrates Bionano's structural variant calls with sequencing data within the Genoox platform.

The Scan

Transplant Tests Edited Pig Kidneys

The Associated Press reports a University of Alabama-Birmingham team transplanted genetically modified pig kidneys into a brain-dead human patient.

UK Changes Some Gene-Edited Crop Rules

A new law may enable gene-edited crops to be sold in the UK within about five years, New Scientist says.

Pill Works Against Omicron in Lab

Pfizer's antiviral pill to treat SARS-CoV-2 appears to work against the Omicron variant, the Wall Street Journal reports.

Nature Papers Find Genetic Risk Factor for Smell, Taste Loss in COVID-19; Analyze TB Granulomas

In Nature this week: genome-wide association study find locus linked to the risk COVID-19 patients losing their sense of taste or smell, and more.